Spartanburg Regional Healthcare System Selects AccessDx Laboratory
In a significant advancement for healthcare, Spartanburg Regional Healthcare System (SRHS) has chosen AccessDx Laboratory as its partner to develop a comprehensive pharmacogenomics (PGx) program. This collaboration aims to empower healthcare providers with vital insights that personalize medication therapies for patients. With a shared commitment to enhancing health equity, the partnership seeks to integrate PGx testing seamlessly into the healthcare process, thereby improving patient outcomes and overall medication efficacy.
Transforming Patient Care Through Pharmacogenomics
The integration of PGx testing allows clinicians to gain insights into how individual patients metabolize various medications. This information is crucial in recognizing potentially harmful drug-gene interactions and ensuring that patients receive the most effective treatment options tailored specifically to their genetic makeup. By implementing this program, SRHS aims to set new standards in patient-centered care.
AccessDx Laboratory’s Role
The selection of AccessDx Laboratory is rooted in its robust track record and commitment to delivering reliable, evidence-based PGx solutions. The laboratory’s services include an array of multispecialty panels that consider rare genetic variants. This rich information enhances prescription accuracy and mitigates the risks associated with medication treatments. AccessDx’s expertise will help SRHS clinicians interpret these tests efficiently, enabling quicker, informed medical decisions.
Expanding Precision Medicine Initiatives
As part of its broader initiative to advance precision medicine, SRHS will initially implement the PGx program across several clinical specialties, including family practice, oncology, maternal-fetal medicine, behavioral health, and pediatrics. This strategic approach is planned for expansion to all clinical settings by 2025, ensuring that PGx insights permeate throughout the healthcare system.
Commitment to Health Equity
Both SRHS and AccessDx Laboratory share a deep commitment to health equity, aiming to enhance healthcare accessibility for all community members. This partnership facilitates the delivery of advanced, precision medicine-based treatments in local settings. As stated by Charles Morrow, MD, Executive Vice President and Chief Operating Officer at SRHS, this collaboration allows clinicians to improve care quality for residents without requiring them to travel far from home for specialized services.
Educational Efforts and Community Engagement
AccessDx Laboratory will not only provide PGx testing but will also work alongside SRHS to develop educational resources for healthcare providers and community members. The goal is to foster greater understanding of pharmacogenomics and its benefits, including potential advancements in patient care experience. Informing all stakeholders—including care teams and patients—through expert content and supplemental training will be a priority in the rollout of this initiative.
Future Directions and Program Goals
Looking ahead, SRHS plans to leverage AccessDx Laboratory’s wealth of knowledge in drug-gene research to establish best practices in pharmacogenomics. By collaborating with leading industry experts, SRHS aims to develop peer-reviewed strategies for assessing risks and tailoring medication to individual patient needs. Ultimately, the objective is to harness PGx's long-term value in guiding treatment options and improving the healthcare journey for all patients.
About Spartanburg Regional Healthcare System
Founded in 1917, Spartanburg Regional Healthcare System (SRHS) is one of the largest providers of healthcare services in its region, committed to advancing health collectively. Operating multiple hospital campuses and numerous offices, SRHS employs over 10,000 staff members and works with approximately 700 physicians, reflecting its dedication to comprehensive healthcare delivery. For further information, visit their official website.
About AccessDx Laboratory
AccessDx Laboratory, part of Aranscia, is a CLIA-certified and CAP-accredited laboratory that specializes in pharmacogenomics, among other diagnostic services. The laboratory prioritizes delivering high-quality, reliable clinical insights that lead to improved patient outcomes. Through extensive research and clinical testing, AccessDx has established its place as a trusted partner for health systems and providers across the nation.
Frequently Asked Questions
What is pharmacogenomics (PGx)?
Pharmacogenomics is the study of how genes affect a person’s response to drugs, allowing for personalized medication plans.
Why is SRHS partnering with AccessDx Laboratory?
SRHS chose AccessDx for their comprehensive approach to PGx and their commitment to health equity, aiming to enhance patient care through tailored treatments.
How will PGx testing benefit patients?
PGx testing can lead to more effective medication regimens, helping avoid adverse drug reactions and improving overall treatment efficacy.
Where will the PGx program be implemented initially?
The program will start in areas such as family practice, oncology, maternal-fetal medicine, behavioral health, and pediatrics, with broader expansion planned.
What resources will be provided by AccessDx Laboratory?
AccessDx will offer expertise, educational materials, and training to healthcare providers and communities to enhance understanding and application of PGx.
